Venoms have repeatedly evolved proteins that exploit the vertebrate coagulation cascade with exceptional potency and selectivity. Our recent research identifies Factor Va as a central, previously underappreciated cofactor in this process. Across phylogenetically diverse venoms, the activation of clotting factors such as prothrombin, Factor VII and Factor X may be weak in isolation but markedly enhanced by Factor Va. Several venoms can also activate Factor V into a functionally active Factor Va cofactor, effectively assembling or amplifying their own procoagulant machinery. This dependence on a defined host cofactor may offer valuable opportunities for the development of conditionally active haemostatic agents.
Australian brown snakes, Pseudonaja species, provide a complementary model for understanding how venom systems regulate not only the speed of clot formation, but also the mechanical properties of the resulting clot. Thromboelastographic studies reveal substantial variation in maximum clot strength. Most brown snake venoms examined generate extremely rapid but comparatively weak and transient clots, whereas venoms from some southern populations of Pseudonaja textilis produce substantially stronger and more stable clots. These contrasting phenotypes occur despite a shared reliance on venom-derived Factor Xa- and Factor Va-like components, indicating that relatively subtle molecular differences can profoundly alter clot architecture, persistence and mechanical stability.
Together, these findings support a translational framework that moves beyond determining whether a venom simply promotes coagulation. Factor Va dependence may provide a biochemical gating mechanism through which activity can be restricted to specific molecular environments, while naturally occurring variation in brown snake venom-induced clot strength offers templates for tuning the balance between rapid haemostasis and clot durability. Identifying the structural and functional determinants responsible for these effects could inform the development of locally acting haemostatic agents, engineered procoagulant complexes, diagnostic reagents and biomaterials designed to produce clots with application-specific properties. Venoms therefore represent not merely a source of potent coagulation activators, but an evolutionary library for controlling when, where and how strongly blood clots.